Omeros' (OMER) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Omeros (NASDAQ:OMER - Free Report) in a report issued on Friday morning,Benzinga reports. D. Boral Capital currently has a $36.00 price objective on the biopharmaceutical company's stock.

Several other research firms have also recently commented on OMER. StockNews.com cut Omeros from a "hold" rating to a "sell" rating in a research report on Friday. Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a research report on Friday, January 17th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $22.50.

Omeros Stock Performance

Shares of OMER stock traded down $0.04 during trading hours on Friday, hitting $8.98. 84,370 shares of the company were exchanged, compared to its average volume of 512,144. The business's 50-day simple moving average is $8.71 and its two-hundred day simple moving average is $7.40. Omeros has a one year low of $2.61 and a one year high of $13.60. The stock has a market capitalization of $520.39 million, a price-to-earnings ratio of -3.89 and a beta of 2.03.

Remove Ads

Institutional Trading of Omeros

A number of institutional investors and hedge funds have recently made changes to their positions in OMER. Two Sigma Investments LP lifted its position in Omeros by 8.8% during the 4th quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company's stock worth $1,610,000 after acquiring an additional 13,201 shares during the last quarter. ProShare Advisors LLC increased its position in Omeros by 75.0% in the 4th quarter. ProShare Advisors LLC now owns 18,496 shares of the biopharmaceutical company's stock worth $183,000 after buying an additional 7,927 shares during the period. Nomura Holdings Inc. lifted its holdings in shares of Omeros by 136.2% during the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company's stock worth $7,383,000 after buying an additional 430,932 shares during the last quarter. Millennium Management LLC grew its stake in shares of Omeros by 46.2% in the fourth quarter. Millennium Management LLC now owns 85,671 shares of the biopharmaceutical company's stock worth $846,000 after acquiring an additional 27,088 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Omeros by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company's stock valued at $314,000 after purchasing an additional 1,110 shares during the period. Institutional investors and hedge funds own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.